- a Covid-19 vaccine maker
- enough cash to last another year
Here's the rub:
- companies need to change their vaccine each year to match circulating strains as required by regulatory agencies, including the U.S. Food and Drug Administration.
- protein-based vaccines like Novavax's take longer to produce than their messenger RNA-based competitors.
Peter Zeihan noted this some time ago.
Will we see similar headlines for EV manufacturers over the next two years? EV manufacturers have other constraints but cash burn is the common bottom line.
No comments:
Post a Comment